Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Ardini

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Frontiers in Oncology|June 2, 2012
ALK Inhibitors, a Pharmaceutical PerspectiveElena Ardini, Arturo Galvani
ESMO Open|September 10, 2020
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic <i>NTRK</i> targeted cancer therapiesElena Ardini, Salvatore Siena
Journal of Medicinal Chemistry|December 17, 2009
Through the "gatekeeper door": exploiting the active kinase conformationFabio Zuccotto, Elena Ardini, Elena Casale, et al.
Drug Discovery Today|July 9, 2004
Reliable high-throughput functional screening with 3-FABSClaudio Dalvit, Elena Ardini, Gian Paolo Fogliatto, et al.
Journal of the American Chemical Society|November 20, 2003
A general NMR method for rapid, efficient, and reliable biochemical screeningClaudio Dalvit, Elena Ardini, Maria Flocco, et al.
Expert Opinion on Therapeutic Targets|March 7, 2013
RET inhibition: implications in cancer therapyMaria Grazia Borrello, Elena Ardini, Laura D Locati, et al.
Cancer Research|March 13, 2002
Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragmentsElena Ardini, Barbara Sporchia, Loredano Pollegioni, et al.
Oncogene|October 19, 2002
p53-dependent downregulation of metastasis-associated laminin receptorMichele Modugno, Elda Tagliabue, Elena Ardini, et al.
Biochemistry|August 11, 2010
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitorsRoberto T Bossi, M Beatrice Saccardo, Elena Ardini, et al.
Oncotarget|September 15, 2017
Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patientMassimo Milione, Elena Ardini, Jason Christiansen, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|June 2, 2012
ALK Inhibitors, a Pharmaceutical PerspectiveElena Ardini, Arturo Galvani
ESMO Open|September 10, 2020
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic <i>NTRK</i> targeted cancer therapiesElena Ardini, Salvatore Siena
Journal of Medicinal Chemistry|December 17, 2009
Through the "gatekeeper door": exploiting the active kinase conformationFabio Zuccotto, Elena Ardini, Elena Casale, et al.
Drug Discovery Today|July 9, 2004
Reliable high-throughput functional screening with 3-FABSClaudio Dalvit, Elena Ardini, Gian Paolo Fogliatto, et al.
Journal of the American Chemical Society|November 20, 2003
A general NMR method for rapid, efficient, and reliable biochemical screeningClaudio Dalvit, Elena Ardini, Maria Flocco, et al.
Expert Opinion on Therapeutic Targets|March 7, 2013
RET inhibition: implications in cancer therapyMaria Grazia Borrello, Elena Ardini, Laura D Locati, et al.
Cancer Research|March 13, 2002
Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragmentsElena Ardini, Barbara Sporchia, Loredano Pollegioni, et al.
Oncogene|October 19, 2002
p53-dependent downregulation of metastasis-associated laminin receptorMichele Modugno, Elda Tagliabue, Elena Ardini, et al.
Biochemistry|August 11, 2010
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitorsRoberto T Bossi, M Beatrice Saccardo, Elena Ardini, et al.
Oncotarget|September 15, 2017
Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patientMassimo Milione, Elena Ardini, Jason Christiansen, et al.
Pageof 2